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Abstract 
The aim of this study was to elucidate the role of fibroblasts in bisphosphonate-related 
osteonecrosis of the jaw (BRONJ), evaluating the effect of zoledronate, alendronate, and 
ibandronate on the proliferation of fibroblasts and on their expression of genes essential for 
fibroblast physiology. Human CCD-1064Sk epithelial fibroblast cells were incubated in culture 
medium with 10-5, 10-7, or 10-9 M zoledronate, alendronate, or ibandronate. The proliferative 
capacity of fibroblasts was determined by spectrophotometry (MTT) at 24 of culture. Real-time 
polymerase chain reaction (RT-PCR) was used to study the effects of BPs at a dose of 10-9 M on the 
expression of FGF, CTGF, TGF-β1, TGFβR1, TGFβR2, TGFβR3, DDR2, α-actin, fibronectin, 
decorin, and elastin. Fibroblasts proliferation was significantly increased at the lowest dose (10-9M) 
of each BP but was not affected at the higher doses (10-5 and 10-7M). The proliferation increase may 
be related to the rise in TGF-β1 and TGFβR1 expression detected after the treatment of cells with 
10-9M of zoledronate, alendronate, or ibandronate. However, the expression of CTGF, DDR2, 
α-actin, fibronectin, and decorin decreased versus controls. The results of this in vitro study indicate 
that a very low BP dose (10-9 M) can significantly affect the physiology of fibroblasts, increasing their 
proliferative capacity and modulating the expression of multiple genes involved in their growth and 
differentiation. 
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Introduction 
Bisphosphonates (BPs) are synthetic analogs of 
pyrophosphate in which the carbon replaces the 
oxygen linking the phosphates. They are commonly 
used for the treatment of some bone disorders like 
osteoporosis, Paget´s disease, multiple myeloma, and 
malignant hypercalcemia.(1) There are two types of 
BP: nitrogen-containing BPs and non-nitrogen- 
containing BPs.(2) The effectiveness of these drugs 
has been demonstrated by several studies , but they 
have also been associated with the development of 
BP-related osteonecrosis of the jaw (BRONJ).(3)   
A reduction in bone turnover and consequent 
accumulation of microfractures, an anti-angiogenic 
effects of BPs, and an alteration on the viability of 
fibroblasts and oral keratinocytes have been 
associated with the development of BRONJ.(4) 
Previous studies of our research group demonstrated 
that high doses of BPs have toxic effects on osteoblasts 
(5) and that low doses reduce their differentiation 
capacity.(6) However, although BPs are known to 
suppress bone turnover, the mechanism by which this 
translates into ulceration of the overlying mucosa 
remains unclear. BPs are known to affect mucosal 








relevance of this effect is unknown.(7) 
Fibroblasts are responsible for forming and 
maintaining soft connective tissue and constitute the 
main source of collagen for the extracellular matrix 
(ECM). They are in a quiescent state in healthy 
conjunctive tissue, being metabolically active but 
unable to proliferate, although they slowly synthetize, 
degrade, and organize the ECM to maintain the tissue 
structure.(8) However, tissue injuries induce major 
changes in cell signaling that translate into cell 
activation, stimulating the formation of granulation 
tissue with a high component of cells (fibroblasts, 
macrophages, myofibroblasts, neovasculature), which 
contributes to the creation of new mature connective 
tissue and favors tissue regeneration.(8) 
The objective of this study was to determine the 
effects of treatment with three nitrogen-containing 
BPs (zoledronate, alendronate, and ibandronate) on 
the proliferation of fibroblasts and on their expression 
of genes essential for fibroblast physiology. 
Material and Methods 
Cell cultures 
 The human CCD-1064Sk epithelial fibroblast cell 
line was purchased from American Type Cultures 
Collection (ATCC, Manassas, VA, USA) (ATCC: CRL- 
2076) and maintained in Dulbecco’s Modified Eagle 
Medium (DMEM; Invitrogen Gibco Cell Culture 
Products, Carlsbad, CA) with 100 IU/mL penicillin 
(Lab Roger SA, Barcelona, Spain), 50 µg/mL gentami-
cin (Braum Medical SA, Jaen, Spain), 2.5 µg/mL 
amphotericin B (Sigma -Aldrich Co. Chem. Comp., St. 
Louis, Mo, USA), 1 % glutamine (Sigma -Aldrich Co), 
and 2 % HEPES (Sigma -Aldrich Co) supplemented 
with 10 % fetal bovine serum (FBS) (Gibco, Paisley, 
UK). Cultures were kept at 37 ºC in humidified 
atmosphere of 95 % air and 5 % CO2. Cells were 
detached from the culture flask with a solution of 0.05 
% trypsin (Sigma-Aldrich Co) and 0.02 % ethylene 
diamine tetra-acetic acid (EDTA) (Sigma -Aldrich Co) 
and were then washed and suspended in complete 
culture medium with 10 % FBS. The study was 
approved by the Ethics Committee of the University 
of Granada. 
Treatments 
The human CCD-1064Sk epithelial fibroblast cell 
line was treated for 24 h with zoledronate (Sigma- 
Aldrich, St. Louis, MO), alendronate (Sigma), or 
ibandronate (Sigma-Aldrich) at doses of 10-5, 10-7, or 
10-9 M, which are within the therapeutic dose 
range.(10) 
Cell proliferation assay 
Fibroblasts were seeded at 1 x 104 cells/mL per 
well into a 24-well plate (Falcon, Becton Dickinson 
Labware, NJ) and cultured at 37 ºC in a humidified 
atmosphere of 95% air and 5% CO2 for 24 h. Next, the 
medium was replaced with DMEM containing 
zoledronate, alendronate, or ibandronate at a dose of 
10-5, 10-7, or 10-9 M. After 24 h of culture, cell 
proliferation was measured by MTT assay, as 
described by Manzano-Moreno et al. (2013).(11) 
Results were expressed with respect the control. At 
least three experiments were conducted for each 
treatment, using the mean value for data analyses. 
RNA extraction and cDNA synthesis (reverse 
transcription) 
 The method described by Manzano-Moreno et 
al. (2018)(12) was used to extract the mRNA of cells 
treated with 10-9 M of zoledronate, alendronate and 
ibandronate and of control cells cultured under the 
same conditions. All assays were run in triplicate. 
Subsequently, an equal amount of RNA (1 μg total 
RNA in 40 μL total volume) was reverse-transcribed 
to cDNA and amplified by PCR using the iScript™ 
cDNA Synthesis Kit (Bio-Rad laboratories, Hercules, 
CA) in accordance with the manufacturer`s 
instructions. 
Real-time polymerase chain reaction 
(q-RT-PCR) 
 The mRNA of fibroblast growth factor (FGF), 
connective tissue growth factor (CTGF), transforming 
growth factor β1 (TGF-β1), transforming growth 
factorβ-receptors (TGFβR1, TGFβR2, and TGFβR3), 
discoidin domain receptor 2 (DDR2), α-actin, 
fibronectin, decorin, and elastin were detected with 
primers designed using the NCBI-nucleotide library 
and Primer3-design (Table 1). All primers were 
designed with NCBI Blast software. Ubiquitin C 
(UBC), peptidylprolyl isomerase A (PPIA), and 
ribosomal protein S13 (RPS13) were used as stable 
housekeeping genes to normalize the final results.(13) 
Quantitative RT-PCR (q-RT-PCR) was per-
formed using the SsoFast™ EvaGreen® Supermix Kit 
(Bio-Rad laboratories) in accordance with the 
manufacturer`s protocol. Standard curves were 
constructed for each target gene by plotting Ct values 
versus log cDNA dilution. After each real-time 
RT-PCR, a melting profile was created and agarose gel 
electrophoresis of each sample was carried out in 
order to rule out non-specific PCR products and 
primer dimers. For the relative quantification of gene 
expression the comparative Ct method was applied. 
The mRNA concentration of each gene was expressed 
in ng of mRNA per average ng of housekeeping 
mRNAs. 





 For the data analyses SPSS 22.0 (IBM, Chicago, 
IL) was used. Mean values (±SD) were calculated for 
each variable. ANOVA was performed to examine the 
effects on proliferation and mRNA levels. When a 
significant interaction was identified, the Bonferroni 
correction was applied for planned pair-wise 
comparisons. At least three experiments were 
conducted for all assays. P ≤ 0.05 was considered 
statistically significant in all tests. 
Results 
Cell proliferation assay 
Each amino-BP under study stimulated 
fibroblast proliferation capacity as a function of the 
dose (Fig. 1). In comparison to controls, a significant 
increase in proliferation was observed in BP-treated 
cells at the lowest dose assayed (10-9 M): zoledronate 
(p=0.004), alendronate (p=0.007), and ibandronate 
(p=0.023). 
Effect of bisphosphonates on the expression of 
genes encoding different growth factors 
(TGF-β1, TGF-β1 receptors, FGF, and CTGF) 
Quantitative RT-PCR (q-RT-PCR) analysis was 
used to evaluate the expression of growth factors 
involved in fibroblast physiology. As depicted in 
Figure 2, cells treated with the BPs at a dose of 10-9 M 
showed increased TGF-β1 and TGFβR1 gene 
expression, with no significant changes in FGF, 
TGFβR2, or TGFβR3 gene expression, and a 
significant reduction in CTGF gene expression. 
 
Table 1. Primer sequences for the amplification of cDNA by 
real-time PCR 




























































Figure 1. Effect of A) zoledronate; B) alendronate; C) ibandronate at different doses (10-5 M, 10-7 M, 10-9 M) on fibroblast proliferation after 24 h of incubation. Data are 
expressed as means + SD. *p ≤ 0.05 





Figure 2. Expression of fibroblast genes (TGF-β1, TGFβR1, TGFβR2, TGFβR3, FGF, and CTGF) treated with zoledronate, alendronate, or ibandronate at a dose of 10-9M. Data 
are expressed as ng of mRNA per average ng of housekeeping mRNAs ± SD. *p ≤ 0.05 
 
Effect of bisphosphonates on the expression of 
genes encoding α-actin, fibronectin, decorin, 
elastin, and DDR2 
Figure 3 depicts the q-RT-PCR results obtained 
for the expression of genes encoding α-actin, 
fibronectin, decorin, elastin, and DDR2. In 
comparison to controls, all three treatments 
significantly reduced the expression of all of these 
genes with the exception of the gene for elastin, whose 
expression was significantly increased. 
Discussion 
The present study demonstrates that in vitro 
treatment with nitrogen-containing BPs at a dose of 
10-9 M increases fibroblast proliferation and 
modulates the expression of the human fibroblast 
markers, TGF-β1, TGFβR1, CTG, α-actin, fibronectin, 
decorin, elastin, and DDR2. The proteins encoding 
these markers play a major role in wound healing by 
stimulating fibroblast proliferation, migration, and/or 
maturation.(14) The proliferation of fibroblasts plays a 
key role in maintaining soft tissue integrity and 
regeneration and was increased by treatment with 
zoledronate, alendronate, or ibandronate, although 
only at the lowest dose assayed (10-9 M); no significant 
changes were detected at doses of 10-5 or 10-7 M. The 
three doses assayed are within the therapeutic dose 
range.(10) 
McLeod et al. 2014 (7) reported that alendronate 
suppressed cell proliferation at 100 μM in human 
fibroblasts, a much higher dose than those assayed in 




our study. Martins et al. 2015 (15) then observed that 
alendronate can inhibit human fibroblast proliferation 
at doses as low as 10 μM. The response of fibroblasts 
to BPs in our study is similar to that observed in 
human osteoblasts, whose proliferative capacity was 
stimulated at very low BP doses but not at higher 
doses, with the observation of toxic effects.(5,6) Song 
et al. 2018 (16) recently reported that the cytotoxic 
effect of BPs on fibroblastic cells depends on their 
dose and concentration. Although a dose of 10-9 M is 
within the therapeutic range of BPs, there is no 
knowledge of the actual concentration reached in soft 
tissue when the drug is released from bone 
hydroxyapatite crystals, where it accumulates during 
long-term BP treatments.(17) 
A complex interplay of different cell types 
(osteogenic cells, oral keratinocytes, fibroblasts, and 
endothelial cells) is needed for a correct wound 
healing in the oral cavity.(18) BRONJ most commonly 
appears after injury to the oral tissues (e.g., after 
dental extraction), and its pathophysiology may arise 
from an effect on these multiple cell types. 
BPs may compromise the function of fibroblasts 
and vessel cells, impairing oral mucosa 
re-epithelialization and nutrition supply.(19) 
Compromised cell function and viability are 
considered to contribute to BRONJ onset alongside a 
fragile and vulnerable oral environment due to thin 




Figure 3. Expression of fibroblasts genes (α-actin, fibronectin, decorin, elastin, and DDR2) treated with zoledronate, alendronate, or ibandronate at dose of 10-9M. Data are 
expressed as ng of mRNA per average ng of housekeeping mRNAs ± SD. *p ≤ 0.05; *p ≤ 0.001 





TGF-β1 exerts multiple functions, including the 
stimulation of fibroblast proliferation, migration, and 
adhesion and the promotion of ECM element 
production.(19) TGF-β1 also favors the maturation of 
fibroblasts, inducing their differentiation to myofibro-
blasts, which are responsible for contractions and for 
synthetizing ECM elements.(21) In the present study, 
TGF-β1 expression was significantly increased after 
treatment with a low dose of BP (10-9 M), which 
would explain the increased proliferative capacity 
observed at this dose alongside the treatment-induced 
increase in expression of one of the TGF-β1 receptors 
(TGFβR1). However, no changes were found in the 
expression of FGFs, the main growth factors for this 
cell population.(22) The BP treatment produced a 
decrease in the expression of CTGF, a multifactorial 
growth factor that participates in ECM regulation and 
synthesis, endothelial cell migration, angiogenesis, 
and fibroblast proliferation and differentiation, 
among other processes.(23) A decrease in CTGF 
expression may affect the regeneration of both hard 
and soft tissues, whose alteration may be the main 
cause of BRONJ development. 
Markers α-actin, fibronectin, decorin, and DDR-2 
are strongly related to fibroblast differentiation/ 
maturation and are therefore involved in tissue 
repair.(24) DDR2 collagen receptors regulate 
fibroblast proliferation and migration and ECM 
synthesis, which are crucial in wound-healing. There 
is also a close relationship between DDR2 and 
MMP-2, predominant proteases in the ECM and 
responsible for wound remodeling. Thus, a decrease 
in DDR2 was reported to reduce migration and 
MMP-2 expression in fibroblasts.(23) In the present 
study, BP treatment decreased the expression of 
DDR-2 in human fibroblasts, which may imply 
inhibition of their migration and MMP-2 expression. 
Treatment with the studied BPs at dose of 10-9M 
was found to increase the expression of elastin, and an 
increase in elastin fibers is known to facilitate 
fibroblast proliferation.(25) It also reduced the 
expression of decorin, which may compromise tissue 
repair because the functions of proteoglycan decorin 
include the regulation of collagen fiber production 
and organization of the ECM alongside the 
enhancement of growth factor bioavailability in this 
matrix.(26)  
Low-dose BP treatment significantly reduced the 
expression of myofibroblast markers α-actin and 
fibronectin. Myofibroblasts present in granulation 
tissue possess intermediate characteristics between 
fibroblasts and smooth muscle cells and play a major 
role in the inflammation, repair, and remodeling of 
tissues. They differentiate from fibroblasts and are 
characterized by the expression of α-actin.(27) The 
significant reduction in these markers may alter the 
differentiation of fibroblasts and therefore their role in 
wound regeneration. 
Studies of osteoblasts by our group (5,6,28) 
demonstrated an increase in their proliferation at low 
concentrations of BPs, similar to the present findings 
in fibroblasts, with a decrease in their differentiation 
capacity and reductions in alkaline phosphatase 
activity, mineralization, and the expression of genes 
related to cell differentiation. Likewise, the present 
study found that a low dose of BPs reduces the 
expression of certain genes related to fibroblast 
differentiation. These findings may be directly related 
to the development of BRONJ through loss of the 
capacity for adequate oral soft tissue repair after 
surgical aggression such as tooth extraction. 
The present results indicate that treatment with 
low BP doses increases the proliferation of fibroblasts 
but reduces the gene expression of markers involved 
in their migration and differentiation of this 
population. Our findings are in concordance whit the 
study of Zafar et al. (29) that showed an increase in 
fibroblasts growth treated with low doses of 
bisphosphonates at short term, meanwhile long-term 
treatment exhibited an adverse effect. These results 
are related with the changes we observed in the gene 
expression study, at 24 h of treatment. 
Thereby altering wound healing, which may 
contribute to BRONJ development in the oral cavity. 
BRONJ is a multifactorial entity and various 
proposals have been made to explain its onset, 
including: a decrease in bone turnover and 
subsequent accumulation of microfractures; a toxic 
effect on osteoblasts (5); an adverse effect on 
osteoclasts (30); an anti-angiogenic effect producing 
avascular necrosis; and a reduction in the viability of 
fibroblasts and oral keratinocytes.(31) However, 
further studies are required to fully elucidate the 
effects of long-term BP consumption on the role of 
fibroblasts in BRONJ. 
In conclusion, the administration of BPs at low 
therapeutic doses increases the proliferative capacity 
of fibroblasts but reduces the expression of genes 
essential for their growth and differentiation. These 
changes may impair the functional capacity of these 
cells at soft tissue level and thereby contribute to 
BRONJ development, alongside other factors. 
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